Cargando…

Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: A prospective, observational cohort study

BACKGROUND: People with end-stage kidney disease, including people on haemodialysis, are susceptible to greater COVID-19 related morbidity and mortality. This study compares the immunogenicity and clinical effectiveness of BNT162B2 versus ChAdOx1 in haemodialysis patients. METHODS: In this observati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martin, Paul, Gleeson, Sarah, Clarke, Candice L., Thomson, Tina, Edwards, Helena, Spensley, Katrina, Mortimer, Paige, McIntyre, Stacey, Cox, Alison, Pickard, Graham, Lightstone, Liz, Thomas, David, McAdoo, Stephen P., Kelleher, Peter, Prendecki, Maria, Willicombe, Michelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463038/ https://www.ncbi.nlm.nih.gov/pubmed/36105885 http://dx.doi.org/10.1016/j.lanepe.2022.100478

Ejemplares similares

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
por: Prendecki, Maria, et al.
Publicado: (2021)

Comparison of Vaccine Effectiveness Against the Omicron (B.1.1.529) Variant in Hemodialysis Patients
por: Spensley, Katrina J., et al.
Publicado: (2022)

Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression
por: Prendecki, Maria, et al.
Publicado: (2021)

Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients
por: Prendecki, Maria, et al.
Publicado: (2021)

Lack of seroresponse to SARS-CoV-2 booster vaccines given early post-transplant in patients primed pre-transplantation
por: Gleeson, Sarah, et al.
Publicado: (2023)

Immune responses following 3rd and 4th doses of heterologous and homologous COVID-19 vaccines in kidney transplant recipients
por: Thomson, Tina, et al.
Publicado: (2022)

SARS-CoV-2 Antibody Point-of-Care Testing in Dialysis and Kidney Transplant Patients With COVID-19
por: Prendecki, Maria, et al.
Publicado: (2020)

COVID-19 vaccination in patients with immunity-mediated kidney disease
por: Prendecki, Maria, et al.
Publicado: (2021)

Temporal changes in complement activation in haemodialysis patients with COVID-19 as a predictor of disease progression
por: Prendecki, Maria, et al.
Publicado: (2020)

Informing the Risk of Kidney Transplantation Versus Remaining on the Waitlist in the Coronavirus Disease 2019 Era
por: Clarke, Candice, et al.
Publicado: (2020)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
por: Barocci, Simone, et al.
Publicado: (2022)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
por: Hermosilla, Eduardo, et al.
Publicado: (2022)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
por: Shrotri, Madhumita, et al.
Publicado: (2021)

Anti–glomerular basement membrane disease during the COVID-19 pandemic
por: Prendecki, Maria, et al.
Publicado: (2020)

Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection
por: Clarke, Candice L., et al.
Publicado: (2021)

Serologic Screening for Coronavirus Disease 2019 in Patients With Glomerular Disease
por: Turner-Stokes, Tabitha, et al.
Publicado: (2021)

Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine
por: Kang, Yu Min, et al.
Publicado: (2021)

Severe COVID‐19 is associated with endothelial activation and abnormal glycosylation of von Willebrand factor in patients undergoing hemodialysis
por: Mobayen, Golzar, et al.
Publicado: (2021)

Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2
por: Tenbusch, Matthias, et al.
Publicado: (2021)

Evaluation of Cellular Responses to ChAdOx1-nCoV-19 and BNT162b2 Vaccinations
por: Lee, Tae Hwan, et al.
Publicado: (2023)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
por: Simpson, C. R., et al.
Publicado: (2021)

Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
por: Simpson, Colin R., et al.
Publicado: (2022)

Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50
por: Xie, Junqing, et al.
Publicado: (2022)

Association of COVID-19 Vaccines ChAdOx1-S and BNT162b2 with Circulating Levels of Coagulation Factors and Antithrombin
por: Hasan, Amal, et al.
Publicado: (2022)

Protective Duration of ChAdOx1 and BNT162b2 Vaccines Against SARS-CoV-2 Infection
por: Alfaleh, Amjad, et al.
Publicado: (2022)

Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021
por: Fortunato, Francesca, et al.
Publicado: (2023)

Plasma Lectin Pathway Complement Proteins in Patients With COVID-19 and Renal Disease
por: Medjeral-Thomas, Nicholas R., et al.
Publicado: (2021)

An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
por: Vallée, Alexandre, et al.
Publicado: (2021)

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
por: Behrens, Georg MN, et al.
Publicado: (2021)

Comparison of S1 antibody titers between BNT162b2 and ChAdOx1 COVID-19 vaccination in cancer patients
por: van Dam, P.A., et al.
Publicado: (2022)

Humoral and cellular responses to vaccination with homologous CoronaVac or ChAdOx1 and heterologous third dose with BNT162b2
por: Hayashi, Jackelinne Y., et al.
Publicado: (2022)

BNT162b2 COVID-19 and ChAdOx1 nCoV-19 vaccination in patients with myelodysplastic syndromes
por: Abdul-Jawad, Sultan, et al.
Publicado: (2022)

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines
por: Wei, Jia, et al.
Publicado: (2022)

Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study
por: Kohmer, Niko, et al.
Publicado: (2023)

Immunogenicity and Durability of Antibody Responses to Homologous and Heterologous Vaccinations with BNT162b2 and ChAdOx1 Vaccines for COVID-19
por: Kim, Dong-In, et al.
Publicado: (2022)

Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19
por: Wei, Jie, et al.
Publicado: (2023)

Myocarditis/pericarditis following vaccination with BNT162b2, CoronaVac, and ChAdOx1 among adolescent and adult in Malaysia
por: Ab Rahman, Norazida, et al.
Publicado: (2023)

Reassurance on bleeding and thrombotic events following second dose BNT162b2 and ChAdOx1 COVID-19 vaccines
por: Pavord, Sue, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2spkam4l0ig96niqpnubgtsdh9